Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Liang H, Wang Q, Wang D, Zheng H, Kalvakolanu DV, Lu H, et al. Corrigendum to "RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-β signaling via SMAD7" [Biochem. Pharmacol. 180 (2020) 114118]. Biochem Pharmacol. 2020;182:114223.

Basourakos SP, Awamlh BA, Bianco FJ, Patel NA, Laviana A, Margolis DJ, et al. Feasibility of in-office MRI-targeted partial gland cryoablation for prostate cancer: an IDEAL stage 2A study. BMJ Surg Interv Health Technol. 2020;2(1):e000056.

Pine AR, Cirigliano SM, Nicholson JG, Hu Y, Linkous A, Miyaguchi K, et al. Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas. Cancer Discov. 2020;10(7):964-979.

Zhong E, Swistel A, Viswanathan K, Hoda SA. Leiomyoma of the Nipple: A common neoplasm in an uncommon location. Breast J. 2020;26(3):529-530.

Izzo F, Lee SC, Poran A, Chaligne R, Gaiti F, Gross B, et al. DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nat Genet. 2020;52(4):378-387.

Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2020;25(2):140-149.

Crowley L, Cambuli F, Aparicio L, Shibata M, Robinson BD, Xuan S, et al. A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. Elife. 2020;9.

Prabhu M, Cagino K, Matthews KC, Friedlander RL, Glynn SM, Kubiak JM, et al. Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study. BJOG. 2020;127(12):1548-1556.

Vickman RE, Faget DV, Beachy P, Beebe D, Bhowmick NA, Cukierman E, et al. Deconstructing tumor heterogeneity: the stromal perspective. Oncotarget. 2020;11(40):3621-3632.

Chaekal O-, Scaradavou A, Frenet EM, Albano MS, Cushing M, Desai P, et al. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020;4(20):5146-5156.